Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01743976 · ClinicalTrials.gov registry record · Phase 4
Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
A Phase 4 study, sponsored by Wake Forest University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT01743976: Clinical Trial Phase 4 study, sponsored by Wake Forest University.
NCT01743976 is a Phase 4 study that was terminated before completion, run by Wake Forest University. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01743976, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
Primary Outcome
A greater number is considered a worse outcome. VAS Range (0-10) 0=No Pain 10=The worst pain imaginable.
Interventions
- DRUG Placebo
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-10-23 |
| Phase | Phase 4 |
Why NCT01743976 stopped before completion
NCT01743976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01743976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01743976 about?
NCT01743976 is a clinical study titled "Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain". Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
What is the current status of trial NCT01743976?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2012-12. Estimated completion is 2013-10-23.
What interventions are being tested in trial NCT01743976?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT01743976?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01743976's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia